Spero Therapeutics (SPRO) EV to EBITDA (2017 - 2026)

Spero Therapeutics (SPRO) has reported EV to EBITDA for 10 consecutive years, with 7.83 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA rose 85.47% year-over-year to 7.83; the trailing twelve-month figure through Jun 2026 stood at 12.9 (up 662.99% YoY), and the FY2025 full-year result was 14.44, up 31796.86% from the prior year.
• EV to EBITDA climbed to 7.83 in Q2 2026 per SPRO's latest filing, from 10.52 in the prior quarter.
• Across five years, EV to EBITDA topped out at 15.35 in Q3 2023 and bottomed at 53.91 in Q2 2025.
• Historically, EV to EBITDA has averaged 3.86 across 5 years, with a median of 0.25 in 2024.
• The widest YoY moves for EV to EBITDA: up 1987.19% in 2025, down 15270.89% in 2025.
• Over 5 years, EV to EBITDA stood at 1.7 in 2022, then soared by 101.83% to 0.03 in 2023, then tumbled by 593.12% to 0.15 in 2024, then surged by 1987.19% to 2.9 in 2025, then tumbled by 369.72% to 7.83 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 7.83, 10.52, and 2.9 for Q2 2026, Q1 2026, and Q4 2025 respectively.